Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
A PHASE4 clinical study on Bone Diseases, Metabolic and Cystic Fibrosis, this trial is completed. The trial is conducted by Centre hospitalier de l'Université de Montréal (CHUM) and has accumulated 5 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Dec 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre hospitalier de l'Université de Montréal (CHUM)
- Laval University
- London Health Sciences Centre
- McGill University
- McMaster University
- Merck Frosst Canada Ltd.
- University of Calgary
For direct contact, visit the study record on ClinicalTrials.gov .